-
1 Comment
Fisher & Paykel Healthcare Corporation Limited is currently in a long term downtrend where the price is trading 7.2% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.3.
Fisher & Paykel Healthcare Corporation Limited's total revenue rose by 59.4% to $910M since the same quarter in the previous year.
Its net income has increased by 86.1% to $226M since the same quarter in the previous year.
Finally, its free cash flow grew by 159.7% to $70M since the same quarter in the previous year.
Based on the above factors, Fisher & Paykel Healthcare Corporation Limited gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Industry | Medical Instruments & Supplies |
Exchange | AU |
CurrencyCode | AUD |
ISIN | NZFAPE0001S2 |
Dividend Yield | 1.2% |
---|---|
Beta | 0.72 |
Market Cap | 19B |
PE Ratio | 155.43 |
Target Price | 33.9809 |
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for FPH.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025